The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great company. Cretinous stock market. Looks like it will be the long way around here to achieve full potential. But up to three fold bagger in next two years for those with a little patience
Your summary of recent market reactions is pretty accurate, Oogleflugal. If anyone doubts it just look at Bango this week where, although their result were disappointing, they hardly warranted a 48% drop on release. All one can hope is that ultimately things will settle down and sound companies that have a good track record, like Avingtrans, will again trade at fair value. Although interest rate reductions may help, this is, unfortunately, unlikely to occur until after the US elections and it may not happen until the situations in Ukraine and the Middle East are resolved. By then, we may be looking at developing situations in the Baltics and Taiwan so I feel that considerable patience may be needed.
Disappointing reaction.more or less expected in this climate . Good results -10 percent , mediocre results -25 percent, bad results -50 percent or ground zero. Paul Hill thinks fair value £9 with the success of Magnetica and Adaptix, which is looking more probable than not . Potential sale to fund investment ? The market is such a dick at the moment. Opportunity though
Don’t know about the weekend but Paul Hill and Chris Harwood both have this at well over £5.00 fair value with nothing added for Adaptix or Magnetica. I guess that is typical of current markets. They did suggest some capital might be required to launch these two companies. The road show they did late last year seems to have been well received. No product likely to get sold till summer. Think that is holding us back at the moment. Just keep adding I think, but bear in mind possible small placing which they would easily get away at current SP and greatly oversubscribed no doubt . Expecting update next week on trading and no doubt Adaptix. Gl
Noticed lot of small transactions early this morning - has the share been tipped over the weekend?
NEWS UPDATE: AVINGTRANS MEDICAL ACTIVITIES (Magnetica & Adaptix together!)
Magnetica Limited
Chicago or bust! Our team is in the air and preparing to converge on Radiological Society of North America (RSNA) 2023 in Chicago in just a few days!
We would love for you to drop by our booth to enjoy some treats and chat about our much-anticipated high-field MSK extremity MRI system. Our prototype system has travelled all the way from Australia and will be available to view from day 1 of the exhibition.
We will be alongside our friends from Adaptix Ltd, and you can visit us at booth number 3141.
Options at £3.9, not exercisable for 3 years from grant date. Now this seems the acceptable face of options, not like some companies that seem to rob shareholders blind. This is fair incentive to staff and fair to shareholders.
Similar article in the IC this week about the sodium pumps.
“Avingtrans (AVG: 378p), a maker of critical engineering components and services, has been awarded a major contract with TerraPower, a high-profile win in the nuclear industry. The nuclear segment accounts for 30 per cent of group revenue.
Co-founded by billionaire Bill Gates in 2008 to create a new cheaper, more efficient and safer type of nuclear power station, TerraPower’s Natrium Rector uses liquid sodium instead of water as a coolant. Its storage capacity enables the release of higher levels of electricity during high demand, too. The heat pump transport system is critical in the reactor, so it’s quite some accolade that Avingtrans’ wholly owned subsidiary, Vermont-based Hayward Tyler, has been awarded a multi-phase $10mn contract by TerraPower to design and develop the heat pumps that circulate the liquid sodium and transfer the coolant. Hayward Tyler has decades of experience in designing large vertical pumps for the existing US civil nuclear fleet, the largest in the world.
Upon completion of the three- to four-year initial phase, TerraPower has the option to have Hayward Tyler manufacture the production pumps for the demonstration project. The award of this contract presents a significant growth prospect within one of Hayward Tyler's core markets.
Orders de-risk earnings guidance
True, the flagship initial order from TerraPower doesn’t impact current year forecasts but it certainly adds to an order book that provides more than 90 per cent visibility for the 2023-24 financial year. The same is true of two national contracts Avingtrans secured last month that aim to make safe nuclear waste for long-term storage of the UK's legacy of nuclear assets. The £14.5mn contract value boosts the order book of Avingtrans’ Metalcraft subsidiary to £75mn over the next six years.
So, although the energy-focused operations are still projected to deliver operating profit of £12mn for the 2023-24 financial year, as a standalone entity the division is worth at least as much as Avingtrans market capitalisation of £124mn. That leaves shareholders with a free ride on the group's medical businesses (‘This energy play has a healthcare arm thrown in for free’, IC, 27 September 2023). Buy.”
Never really went away formerlyeatp. Its the transition to nuclear fusion that is the next big step. The germans got a bad case of paranoia after Japan experienced some catastrophic problems with tsunamis and overheating reactors. The Germans must be ruing the decision to ban all nuclear power after the fall out with Russia. There are so many parts to AVG, maybe too many for such a small company. They are very good though at taking on small innovative companies that are struggling, putting them back on their feet and selling them off again. Adaptix is a case in point. They completed a full takeover recently of this potentially revolutionary portable scanning inventor that could have markets in medical and aerospace industries. They ran out of money so Avg stepped in at a bargain price. Will require some funding to launch the product next year hopefully which seems to be dragging on the sp currently. Absolute bargain at these prices IMO. More than 100% plus upgrade possible in next couple of years. Obviously not without risk, but nothing is risk free.
Interesting company had not seen it until this mornings RNS. Is nuclear power making a come back, hope so.
Great nuclear contract news as flagged up in updates if only the market would pay attention. Confirmation is Impressive none the less
Helllo , anyone out there? Avg not actually involved with the bit of Hs2 that is being cancelled.
Https://www.proactiveinvestors.co.uk/companies/news/1027859/avingtrans-in-a-strong-cash-position-after-beating-city-expectations-again-1027859.html
https://www.proactiveinvestors.co.uk/companies/news/1027852/avingtrans-results-ahead-of-broker-forecasts-as-energy-arm-pushes-ahead-1027852.html
Would you guess result tomorrow, with all these late reported tradesFortunately got my top ups by end of last week. Hoping for some really interesting good news
Last message from Adaptix was regarding their Non-destructive testing application otherwise surprisingly absent is progress with orthopaedic particularly in the USA.
Needed soon is clarification as to whether Adaptix and Magnetica will be going it alone or more closely. There needs to be a proposed timeline with stages as to where the medical activities go from here. Are we still looking for an IPO at some point? If so when?
Hopefully they will provide comprehensive answers with the results next week.
Meantime a rather muted response from the market albeit buyers rather than sellers..
I’ve bought and sold kmk 3 times and made a small amounts each time. Has been an excellent trading stock. I stopped because It was obvious lending was tightening up and as your excellent report points to the problem of scaling up to fill the market size they would like to attain. It’s seems they are in a continual spiral the wrong way. Their first big hype was the radiation detector which doesn’t appear to have attracted the game changing orders they or Thompson forecast. It’s a fast moving sector with constant and regular updates and revisions are needed to keep pace with the competition. Avg seem to have potential industry standard equipment that will be in service for years. Kmk is sort of tempting at 5p but 13 years without profit and almost annual raises are a bit of a clue about their predicament. Avg latest deal is to buy a 80 percent of a company for less than their initial 10 percent stake. Careful what you wish for!
To be honest Oogleflugal I am not sure, hence why I said there appears to be synergy between the medical part and potentially the nuclear arm of Avingtrans with Kromek. I am literally flying a kite in the hope that Avingtrans will give the matter some thought and if synergy exists and it is attractive, benefit will follow. If it is a non starter, Avingtrans should of course keep well clear. Just in case other readers have more detailed knowledge and would like to express a view, I provide the following link to Kromek which may be informative and of interest.
https://www.lgbco.com/quoted-landing-page/the-future-of-healthcare/kromek/
Are you sure about their products. I see kmk as a bit of a gadget company. Don’t think that would fit here. Must have had about ten raises so far. Dilution is spectacular. Avg medical arm is producing an almost portable scanner. This really could be massive. Interesting that they are focusing on the States first. Market seems to have woken up to that thisafternoon
I keep hoping that Avingtrans will work their magic on Kromek, which has good products but dismal management. It appears as if there would be synergy in such a takeover so I continue to live in hope, rather than expectation.
Am waiting to see what stockopedia make of it. It is a bit jam tomorrow on the scan and x-ray combination but what a bumper crop that could be. As to the rest of the business as Chris Mills says more than backs up the current sp. So the medical side is a free ride!
Surprising announcement regarding the possible acquistiion of the Adaptix equity they do not already own - by issuing new Avingtrans shares to value of £3m. Interesting development - need more info hopefully by end of next week! If it goes ahead they may need to provide the business through already underway commercialisation of it's technology with new funds.
I wonder what Simon Thompson (Investors Chronicle) will make of this?
Very solid inline update. Possible completion of the rest of Adaptix which has phenomenal potential. Great under the radar stock in the Harwood capital folio. Looks very good value still . Could rerate again this year
Magnetica (Avingtrans Medical holding) is expected to be present this week with it's niche MRI Scanner technology:-
They stated :- We shall be attending and exhibiting at the next ESSR (European Society of Musculoskeletal Radiology) annual scientific meeting.
ESSR 2023 – 30th Annual Scientific Meeting, Dates: 22nd to 24th June 2023
Location: Bilbao, Biscay, Spain
Would be interested to hear more?